Biotest AG: Biotest Supervisory Board extends contracts with the Board of Management
DGAP-News: Biotest AG
/ Key word(s): Personnel
Biotest Supervisory Board extends contracts with the Board of Management
- Appointment of Chief Executive Officer and Chief Financial Officer Dr. Michael Ramroth extended
- Appointment of Chief Operations Officer Dr. Georg Floß extended
The new term of office and Management Board contract of Dr. Michael Ramroth (59) has a term of three years until December 31, 2023.
The term of office and the Management Board contract of Dr. Georg Floß (59) was extended by two years until January 8, 2023.
The distribution of responsibilities within the Management Board remains unchanged.
"The cooperation between the Supervisory Board and the Management Board is based on trust, is open and always result-oriented. Consequently, a prolongation and continuity during a strategically extremely important phase is expressly desired by the entire Supervisory Board and we are pleased that this has been achieved in both cases," emphasized the Chairman of the Supervisory Board, Rolf Hoffmann.
With the two members of the Management Board, Dr. Ramroth and Dr. Floß, the Biotest Next Level expansion project at the Dreieich site was successfully advanced, thus placing Biotest AG's growth course on a solid footing. The extension of the contracts ensures the continuity of the trusting relationships with the company's lenders and shareholders.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
20.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1096607|
|End of News||DGAP News Service|